<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735952</url>
  </required_header>
  <id_info>
    <org_study_id>331178/ H20-00071</org_study_id>
    <secondary_id>Pro00043176</secondary_id>
    <secondary_id>HILL18A0</secondary_id>
    <secondary_id>R56HL139846</secondary_id>
    <nct_id>NCT04735952</nct_id>
  </id_info>
  <brief_title>Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath)</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Arizona State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital Colorado</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cystic Fibrosis Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a breath biomarker validation study. It is anticipated that 300 patients with&#xD;
      cystic fibrosis (CF) from 5 clinical sites in the USA will be enrolled. The study is funded&#xD;
      by the US NIH and the US Cystic Fibrosis Foundation. Enrollment commenced in May 2019.&#xD;
      Sputum, induced sputum, and oropharyngeal swabs will be collected and evaluated at each&#xD;
      clinic as part of standard clinical practice. Excess sputum will be sent to Children's&#xD;
      Colorado Hospital for molecular analysis. No swabs will be sent anywhere (other than the&#xD;
      clinic from which they originate). Breath samples will be taken from all study participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AIM 1: Refine and validate volatile biomarkers in the breath of adult and pediatric CF&#xD;
      patients for detecting established P. aeruginosa lung infections. For each expectorating&#xD;
      subject (n ≥ 288; 5 centers), the diagnostic accuracy of the volatile biomarker panel will be&#xD;
      tested, with sputum culture as the standard.&#xD;
&#xD;
      AIM 2: Quantify intra-subject breath variability of the target pediatric population. We will&#xD;
      collect longitudinal breath samples for two years from P. aeruginosa-negative subjects (n ≥&#xD;
      58; ~60% non-expectorating) at 4 pediatric CF clinical centers. We will measure intra-subject&#xD;
      variance in the breath signatures of expectorating and non-expectorating subjects, with the&#xD;
      latter being the target population for the clinical trial. Two to 8 breath samples will be&#xD;
      collected per patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in concentrations of individual volatile biomarkers and combinations of biomarkers in breath samples obtained from persons with and without P. aeruginosa lung infections</measure>
    <time_frame>Enrollment thru 2023. Last Longitudinal Study Visit will be 24 months after last AIM 2 enrollment</time_frame>
    <description>Measured using comprehensive two-dimensional gas chromatography of exhaled breath compared to sputum culture (gold standard)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-subject changes in concentrations of individual volatile biomarkers and combinations of biomarkers in breath samples</measure>
    <time_frame>Thru end of 2025</time_frame>
    <description>Breath samples obtained over a duration of two years, measured using comprehensive two-dimensional gas chromatography of exhaled breath</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>AIM 1</arm_group_label>
    <description>No-Intervention. Participants in this group will have 1 study visit only. During that visit, breath and sputum samples will be collected.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIM 2</arm_group_label>
    <description>No-Intervention. Participants in this group will have up to 8 study visits over a 2 year period. During the study visits, breath and sputum samples will be collected.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Breath Samples (The act of analyzing the sample will completely deplete the sample.) Sputum&#xD;
      Samples (A portion of the sample may be retained)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will have a diagnosis of cystic fibrosis with cultures that are either P.&#xD;
        aeruginosa (Pa) negative or Pa positive.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aim 1, Cross-Sectional&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, ages 8 years and older&#xD;
&#xD;
          2. Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations&#xD;
&#xD;
          3. Able to expectorate sputum spontaneously or willing to undergo sputum induction&#xD;
             procedure&#xD;
&#xD;
          4. FEV1 ≥ 30% predicted for spontaneous expectorators or FEV1 ≥ 40% predicted for&#xD;
             subjects undergoing sputum induction&#xD;
&#xD;
          5. Either P. aeruginosa (Pa) negative or chronically infected with P. aeruginosa (Pa&#xD;
             positive) as defined below:&#xD;
&#xD;
             a. P. aeruginosa negative: must meet one of the following criteria: i. No growth of Pa&#xD;
             in previous 12 months and ≥ 4 consecutive Pa-negative cultures, OR ii. No history of&#xD;
             Pa positive airway cultures (sputum, OP, Bronchoalveolar lavage) b. P. aeruginosa&#xD;
             positive i. Over 50% of cultures positive and at least 2 cultures positive for Pa in&#xD;
             previous 18 months&#xD;
&#xD;
          6. Willing to participate in and comply with the study procedures and willingness of the&#xD;
             subject, parent or legally authorized representative to provide written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Age &lt; 8 years&#xD;
&#xD;
          2. Intermittently infected with Pa&#xD;
&#xD;
          3. Unable to expectorate sputum or undergo sputum induction&#xD;
&#xD;
          4. FEV1 &lt; 30%&#xD;
&#xD;
          5. History of lung transplant&#xD;
&#xD;
          6. Presence of a condition or abnormality that in the opinion of the Principal&#xD;
             Investigator would compromise the safety of the subject or the quality of the data.&#xD;
&#xD;
        Aim 2, Longitudinal&#xD;
&#xD;
        Inclusion Criteria, Expectorating Cohort (n=48):&#xD;
&#xD;
          1. Male or female, ages 8-16 years&#xD;
&#xD;
          2. Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations&#xD;
&#xD;
          3. Able to expectorate sputum spontaneously or willing to undergo sputum induction&#xD;
             procedure&#xD;
&#xD;
          4. FEV1 ≥ 30% predicted for spontaneous expectorators or FEV1 ≥ 40% predicted for&#xD;
             subjects undergoing sputum induction&#xD;
&#xD;
          5. P. aeruginosa negative, based on one of the following criteria:&#xD;
&#xD;
               1. No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures&#xD;
&#xD;
               2. No history of Pa positive airway cultures (sputum, OP, bronchoalveolar lavage)&#xD;
&#xD;
          6. Willing to participate in and comply with the study procedures and willingness of the&#xD;
             subject, parent or legally authorized representative to provide written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Age &lt; 8 years&#xD;
&#xD;
          2. Intermittently or chronically infected with Pa&#xD;
&#xD;
          3. Unable to expectorate sputum or undergo sputum induction&#xD;
&#xD;
          4. FEV1 &lt; 30%&#xD;
&#xD;
          5. History of lung transplant&#xD;
&#xD;
          6. Presence of a condition or abnormality that in the opinion of the Principal&#xD;
             Investigator would compromise the safety of the subject or the quality of the data.&#xD;
&#xD;
        Inclusion Criteria, Non-Expectorating Cohort (n=10):&#xD;
&#xD;
          1. Male or female, ages 3-8 years&#xD;
&#xD;
          2. Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations 3.&#xD;
             FEV1 ≥ 30%&#xD;
&#xD;
        4. Unable to expectorate sputum 5. P. aeruginosa negative, based on one of the following&#xD;
        criteria:&#xD;
&#xD;
          1. No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures&#xD;
&#xD;
          2. No history of Pa positive airway cultures (sputum, OP, bronchoalveolar lavage) 6.&#xD;
             Willing to participate in and comply with the study procedures and willingness of the&#xD;
             subject, parent or legally authorized representative to provide written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Age &lt; 3 years&#xD;
&#xD;
          2. Intermittently or chronically infected with Pa&#xD;
&#xD;
          3. FEV1 &lt; 30%&#xD;
&#xD;
          4. History of lung transplant&#xD;
&#xD;
          5. Presence of a condition or abnormality that in the opinion of the Principal&#xD;
             Investigator would compromise the safety of the subject or the quality of the data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane E Hill, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane E Hill, PhD</last_name>
    <phone>778 879 5105</phone>
    <email>jane.hill@ubc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kathy J Phipps, BA</last_name>
    <phone>603-646-3056</phone>
    <email>kathy.j.phipps@dartmouth.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Phoenix Children's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophia Williams, MD</last_name>
      <phone>602-933-0985</phone>
      <email>swilliams5@phoenixchildrens.com</email>
    </contact>
    <contact_backup>
      <last_name>Natalia Argel</last_name>
      <phone>602-933-0985</phone>
      <email>nargel@phoenixchildrens.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edith Zemanick, MD</last_name>
      <phone>720-777-5426</phone>
      <email>Edith.Zemanick@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Sanchez</last_name>
      <phone>720-777-4949</phone>
      <email>jennifer.sanchez@childrenscolorado.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerry Nick, MD</last_name>
      <phone>303-398-1579</phone>
      <email>NickJ@NJHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Katie Poch</last_name>
      <phone>3033981255</phone>
      <email>pochk@njhealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brian O'Sullivan, MD</last_name>
      <email>Brian.P.O'Sullivan@hitchcock.org</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Phipps, BA</last_name>
      <phone>8026839291</phone>
      <email>kathy.j.phipps@dartmouth.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary McPhail, MD</last_name>
      <phone>513-636-6771</phone>
      <email>Gary.McPhail@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Kira Proulx</last_name>
      <phone>513-636-8449</phone>
      <email>Kira.Proulx@cchmc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://impactbreath.org</url>
    <description>Public access to study information and clinical site portal.</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jane Hill, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Breath</keyword>
  <keyword>IMPACT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

